

FIG. 5

FIG. 5




FIG. 6




FIG. 7




FIG. 7A





FIG. 8



0997822-13001  
FIG. 9

FIG. 9





FIG. 10



FOOT" 22826660

44

10

FIG.13



FIG.11

12

46

46

48






FIG.12

44

48

46



BEST AVAILABLE COPY

FIG. 14





FIG. 15



FOOT" 223/6660

BEST AVAILABLE COPY

FIG. 16





FIG. 17



FOOT 1 228/6560



BEST AVAILABLE COPY

FIG. 18





FIG. 19



FOOT" 228/6660

BEST AVAILABLE COPY

FIG. 20





FIG. 21



100E11" 22B/6660

BEST AVAILABLE COPY

FIG. 22





FIG. 23



FOUETT-228/6660

FIG. 24






FIG. 25




# FIG. 26

Levels of Acridine derivative in PRBC treated with 200  $\mu$ M Acridine Compound and 2 mM GSH




# FIG. 27

Total level of Glutathione (oxidized and reduced) in  
PRBC treated with 200  $\mu$ M Acridine Compound and 2  
mM GSH



# FIG. 28

% Hemolysis in PRBCs treated with  
200  $\mu$ M Acridine Compound and 2 mM GSH



0597222-113001